Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 564

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 3
Chunk 564
---
From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

As
of March 12, 2025, there are no pending material legal proceedings, and we are currently not aware of any legal proceedings or claims
against us or our property that we believe will have any significant effect on our business, financial position or operating results.
None of our officers or directors is a party against us in any legal proceeding.

Item
4. Mine Safety Disclosures.

Not
applicable.

PART
II

Item
5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market
Information

Our
common stock is listed on the Nasdaq Capital Market under the name “Indaptus Therapeutics, Inc.” and ticker symbol “INDP”.

Holders

As
of March 12, 2025, we had 22 record holders of our common stock. This number does not include the number of persons whose shares are
in nominee or in “street name” accounts through brokers.

Dividend
Policy

We
have never declared or paid cash dividends to our shareholders, and we do not intend to pay cash dividends in the foreseeable future.
We intend to reinvest any earnings in developing and expanding our business. Any future determination relating to our dividend policy
will be at the discretion of our board of directors and will depend on a number of factors, including our financial condition, operating
results, contractual restrictions, capital requirements, business prospects, our strategic goals and plans to expand our business, applicable
law and other factors that our board of directors may deem relevant.

Securities
Authorized for Issuance under Equity Compensation Plans

Information
about our equity compensation plan under which the Company’s equity securities are authorized for issuance is set forth in “Part
III - Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” of this Annual Report.

Recent
Sales of Unregistered Securities

None.

Purchases
of Equity Securities by the Issuer and Affiliated Purchasers

We
did not repurchase any of our equity securities during the quarter ended December 31, 2024.

Item
6. [Reserved]

63

Item
7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You